

**Amendments to the Specification:**

After the title but before the first paragraph, please insert the following new paragraph:

**CROSS REFERENCE TO RELATED APPLICATIONS**

This application is a 371 filing of PCT International application no. PCT/IL2003/001040 filed December 9, 2003 and published in English as WO 04/053054 on June 24, 2004 which claims the priority of U.S. Application No. 60/431,728 on December 9, 2002, the disclosures of which are hereby incorporated by reference in their entirety.

On a separate page, page 41, please insert the following abstract:

**NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES****ABSTRACT OF THE INVENTION**

The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells *in vivo*. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an agent capable of exerting a cytotoxic effect on the tumor cell. The target recognition segment derived from the natural killer receptor NKp30 has been found to be particularly effective *in vivo*.